Collegium Pharmaceutical, Inc. $COLL Stock Position Lifted by Quantinno Capital Management LP

Posted by on Aug 12th, 2026

Quantinno Capital Management LP grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 195.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 56,242 shares of the specialty pharmaceutical company’s stock after acquiring an additional 37,213 shares during the quarter. Quantinno Capital Management LP owned approximately 0.17% of Collegium Pharmaceutical worth $1,860,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in Collegium Pharmaceutical by 59.1% in the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after purchasing an additional 538,337 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Collegium Pharmaceutical by 65.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after purchasing an additional 518,721 shares during the period. Millennium Management LLC raised its holdings in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares during the period. Two Sigma Investments LP lifted its position in shares of Collegium Pharmaceutical by 897.2% in the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock worth $9,423,000 after buying an additional 242,310 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in shares of Collegium Pharmaceutical by 237.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock worth $11,216,000 after buying an additional 225,679 shares during the last quarter.

Collegium Pharmaceutical Stock Down 4.5%

Collegium Pharmaceutical stock opened at $25.98 on Wednesday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. Collegium Pharmaceutical, Inc. has a one year low of $25.90 and a one year high of $50.79. The company has a 50-day simple moving average of $34.60 and a 200-day simple moving average of $36.72. The firm has a market capitalization of $845.80 million, a P/E ratio of 20.95 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. Collegium Pharmaceutical’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the firm posted $1.68 EPS. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on COLL shares. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday. Piper Sandler reissued a “neutral” rating and issued a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Needham & Company LLC decreased their target price on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $52.60.

Check Out Our Latest Stock Report on COLL

Collegium Pharmaceutical Company Profile

(Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

Read More

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.